Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.

STI571 (formerly known as CGP 57148B) is a protein-tyrosine kinase inhibitor that is currently in clinical trials for the treatment of chronic myelogenous leukemia. STI571 selectively inhibits the Abl and platelet-derived growth factor (PDGF) receptor tyrosine kinases in vitro and blocks cellular proliferation and tumor growth of Bcr-abl- or v-abl-expressing cells. We have further investigated the profile of STI571 against related receptor tyrosine kinases. STI571 was found to potently inhibit the kinase activity of the alpha- and beta-PDGF receptors and the receptor for stem cell factor, but not the closely related c-Fms, Flt-3, Kdr, Flt-1, and Tek tyrosine kinases. Additionally, no inhibition of c-Met or nonreceptor tyrosine kinases such as Src and Jak-2 has been observed. In cell-based assays, STI571 selectively inhibited PDGF and stem cell factor-mediated cellular signaling, including ligand-stimulated receptor autophosphorylation, inositol phosphate formation, and mitogen-activated protein kinase activation and proliferation. These results expand the profile of STI571 and suggest that in addition to chronic myelogenous leukemia, STI571 may have clinical potential in the treatment of diseases that involve abnormal activation of c-Kit or PDGF receptor tyrosine kinases.

[1]  S. Honsawek,et al.  The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  E. Buchdunger,et al.  Role of platelet-derived growth factor in obliterative bronchiolitis (chronic rejection) in the rat. , 1999, American journal of respiratory and critical care medicine.

[3]  C. Moskaluk,et al.  Activating c-kit gene mutations in human germ cell tumors. , 1999, The American journal of pathology.

[4]  D. Heitjan,et al.  Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[5]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[6]  M. Carroll,et al.  CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. , 1997, Blood.

[7]  S. Hirota,et al.  Ultrastructural identification of the c-kit-expressing interstitial cells in the rat stomach: a comparison of control and Ws/Ws mutant rats , 1997, Cell and Tissue Research.

[8]  Jürg Zimmermann,et al.  Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives , 1997 .

[9]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[10]  G. Krystal,et al.  Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. , 1996, Cancer research.

[11]  G. Krystal,et al.  Coexpression of the c-kit and stem cell factor genes in breast carcinomas. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[12]  C. Heldin,et al.  Dimerization of cell surface receptors in signal transduction , 1995, Cell.

[13]  R. Ross,et al.  Growth Regulatory Mechanisms and Formation of the Lesions of Atherosclerosis a , 1994, Annals of the New York Academy of Sciences.

[14]  I. Mcniece,et al.  Stem cell factor. , 1995, Journal of leukocyte biology.

[15]  H. Inui,et al.  Differences in signal transduction between platelet-derived growth factor (PDGF) alpha and beta receptors in vascular smooth muscle cells. PDGF-BB is a potent mitogen, but PDGF-AA promotes only protein synthesis without activation of DNA synthesis. , 1994, The Journal of biological chemistry.

[16]  S. Sartore,et al.  Smooth-muscle-cell proliferation and differentiation in neointima formation and vascular restenosis. , 1994, Clinical science.

[17]  S. Kyo,et al.  Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors. , 1994, Cancer research.

[18]  N. Lydon,et al.  4,5-Dianilinophthalimide: a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[19]  C. Heldin,et al.  Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[20]  R. Nakhleh,et al.  Obliterative bronchiolitis after lung transplantation: a fibroproliferative disorder associated with platelet-derived growth factor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[21]  K. Zsebo,et al.  Nonhematopoietic tumor cell lines express stem cell factor and display c-kit receptors. , 1992, Blood.

[22]  E. Thiel,et al.  Recombinant human stem cell factor stimulates growth of a human glioblastoma cell line expressing c-kit protooncogene. , 1992, Cancer research.

[23]  C. Heldin,et al.  Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. , 1992, Cancer research.

[24]  D. Gordon.  Growth factors and cell proliferation in human transplant arteriosclerosis. , 1992, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[25]  T Takahashi,et al.  Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. , 1991, Oncogene.

[26]  M. Reidy,et al.  Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF , 1991, Science.

[27]  R. Ueda,et al.  Preferential expression of c-kit protooncogene transcripts in small cell lung cancer. , 1991, Cancer research.

[28]  A. Ullrich,et al.  Expression of the hst-1 and c-kit protooncogenes in human testicular germ cell tumors. , 1991, Cancer research.

[29]  K. Zsebo,et al.  Recombinant human stem cell factor synergises with GM-CSF, G-CSF, IL-3 and epo to stimulate human progenitor cells of the myeloid and erythroid lineages. , 1991, Experimental hematology.

[30]  L. Cantley,et al.  The colony stimulating factor-1 receptor associates with and activates phosphatidylinositol-3 kinase , 1989, Nature.

[31]  A. Bernstein,et al.  Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice--evidence for an impaired c-kit kinase in mutant mice. , 1989, Genes & development.

[32]  C. Heldin,et al.  Rat brain capillary endothelial cells express functional PDGF B-type receptors. , 1989, Growth factors.

[33]  Jonathan A. Cooper,et al.  Different effects of homo‐ and heterodimers of platelet‐derived growth factor A and B chains on human and mouse fibroblasts. , 1988, The EMBO journal.

[34]  C. Heldin,et al.  Binding of different dimeric forms of PDGF to human fibroblasts: evidence for two separate receptor types. , 1988, The EMBO journal.

[35]  H. Antoniades,et al.  Constitutive production of platelet-derived growth factor-like proteins by human prostate carcinoma cell lines. , 1988, Cancer research.

[36]  C. Heldin,et al.  Frequent expression of growth factors for mesenchymal cells in human mammary carcinoma cell lines. , 1987, Cancer research.

[37]  Gary R. Grotendorst,et al.  Platelet-derived growth factor in chemotactic for fibroblasts , 1982, The Journal of cell biology.